Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024: Focus on Blood Pressure and Lipids.
Med Clin North Am
; 108(3): 441-453, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38548456
ABSTRACT
Hypertension and dyslipidemia are 2 highly prevalent and modifiable risk factors in patients with stable ischemic heart disease. Multiple lines of evidence demonstrate that lowering blood pressure and low-density lipoprotein cholesterol improves clinical outcomes in patients with ischemic heart disease. Accordingly, clinical guidelines recommend intensive treatment targets for these high-risk patients. This article summarizes the pathophysiology, supporting evidence, and treatment recommendations for management of hypertension and dyslipidemia among patients with manifest ischemic heart disease and points to future research and unmet clinical needs.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myocardial Ischemia
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Dyslipidemias
/
Hypertension
Limits:
Humans
Language:
En
Journal:
Med Clin North Am
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: